Slingshot Pulls Therapy Chatbot Ash Out of UK Over Regulations
- Slingshot AI will withdraw its therapy chatbot submission, Ash, from the United Kingdom this week due to concerns about compliance with the country's medical device regulations.
- Ash, designed to provide mental health support through an AI chatbot, has faced questions regarding its classification as a medical device.
- According to a report by STAT News, the MHRA issued a warning to Slingshot AI on January 18, 2024, stating that Ash was being supplied as a medical...
Slingshot AI to Remove Therapy Chatbot Ash from the UK Market
Table of Contents
Slingshot AI will withdraw its therapy chatbot submission, Ash, from the United Kingdom this week due to concerns about compliance with the country’s medical device regulations. The decision comes after scrutiny from the Medicines and Healthcare products Regulatory Agency (MHRA), which regulates medical devices in the UK.
Regulatory Concerns and MHRA Scrutiny
Ash, designed to provide mental health support through an AI chatbot, has faced questions regarding its classification as a medical device. The MHRA determined that ash functions as a medical device, requiring regulatory approval before being legally marketed in the UK. Slingshot AI’s CEO, Daniel reid Cahn, acknowledged these concerns in a statement to the press.
According to a report by STAT News, the MHRA issued a warning to Slingshot AI on January 18, 2024, stating that Ash was being supplied as a medical device without the necesary regulatory approvals. STAT News Report
What is a Medical Device in the UK?
In the UK, a medical device is defined as any instrument, apparatus, appliance, software, implant, reagent or similar article intended by its manufacturer to be used for a medical purpose. This includes diagnosis,prevention,monitoring,treatment or alleviation of disease. The MHRA regulates medical devices to ensure they are safe and effective. MHRA Medical Device Guidance
slingshot AI’s Response and future Plans
Slingshot AI has decided to withdraw Ash from the UK market rather than pursue the necessary regulatory approvals. CEO Daniel Reid Cahn stated the company believes the regulatory pathway is too complex and costly. The company will continue to offer Ash in the United States, where the regulatory landscape for AI-powered mental health tools is currently less defined.
Cahn indicated that Slingshot AI is focusing its efforts on the U.S. market and exploring potential regulatory strategies there. He also expressed frustration with the UK’s regulatory approach, suggesting it hinders innovation in the AI healthcare space. STAT News Report
Implications for the AI Mental Health Industry
This situation highlights the growing regulatory scrutiny surrounding AI-powered mental health applications. The MHRA’s action sends a clear signal to other companies in this space that they must comply with medical device regulations if their products function as medical devices.The UK’s approach may influence regulatory developments in other countries, including the United States.
The MHRA’s enforcement action against Slingshot AI underscores the importance of understanding and adhering to medical device regulations when developing and deploying AI-based healthcare solutions. The agency’s website provides detailed details on the requirements for medical device approval in the UK. MHRA Medical Device Guidance